RECRUITING

Antihypertensive Mechanisms of Minocycline in Resistant Hypertension

Conditions

Hypertension, Resistant to Conventional Therapy minocycline blood pressure

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this clinical trial is to learn about the mechanisms by which minocycline effect blood pressure in individuals with treatment-resistant hypertension. The main questions it aims to answer are: * To what extent does minocycline lower blood pressure? * Are such blood pressure effects mediated through changes in gut microbiota, gut leakiness, systemic inflammation, neuroinflammation, or some combination of these? Participants will be randomly assigned to treatment with minocycline or placebo, treated daily for 3 months, to evaluate these questions.

Official Title

Antihypertensive Mechanisms of Minocycline in Resistant Hypertension: Role of the Gut Microbiota-brain-immune Axis

Quick Facts

Study Start:2025-01-08

Study Completion:2028-07

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT06246396

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 85 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Age ≥18 years * Uncontrolled TRH, defined as uncontrolled blood pressure (mean 24-hour ambulatory systolic BP ≥125 mm Hg or diastolic BP ≥80 mm Hg) while being adherent to a stable (no changes in ≥14 days prior) antihypertensive regimen of 3 or more drugs, including an adequately dosed diuretic or unable to tolerate a diuretic. * The participant agrees to have all study procedures performed	* Known hypersensitivity or contraindication to minocycline or other tetracyclines * Recent (≤3 months prior), ongoing, or expected use of oral antibiotics * Estimated glomerular filtration rate (eGFR) of \<45mL/min/1.73m2, using the MDRD equation * Known secondary hypertension * History of hypertensive crisis, defined as any in-patient hospitalizations for hypertensive crisis/emergency within the past year * History of orthostatic hypotension, defined as two or more episode(s) of orthostatic hypotension (reduction of SBP of \>20 mm Hg or DBP of \>10 mm Hg within 3 minutes of standing) in the past year * History of myocardial infarction, unstable angina, syncope, or cerebrovascular accident in prior 6 months * Evidence of alcoholism or drug abuse * Severe comorbid conditions (i.e., neoplasms or HIV positive or AIDS) * Current pregnancy or anticipated pregnancy during the study.

Inclusion Criteria

Exclusion Criteria

* Age ≥18 years
* Uncontrolled TRH, defined as uncontrolled blood pressure (mean 24-hour ambulatory systolic BP ≥125 mm Hg or diastolic BP ≥80 mm Hg) while being adherent to a stable (no changes in ≥14 days prior) antihypertensive regimen of 3 or more drugs, including an adequately dosed diuretic or unable to tolerate a diuretic.
* The participant agrees to have all study procedures performed

* Known hypersensitivity or contraindication to minocycline or other tetracyclines
* Recent (≤3 months prior), ongoing, or expected use of oral antibiotics
* Estimated glomerular filtration rate (eGFR) of \<45mL/min/1.73m2, using the MDRD equation
* Known secondary hypertension
* History of hypertensive crisis, defined as any in-patient hospitalizations for hypertensive crisis/emergency within the past year
* History of orthostatic hypotension, defined as two or more episode(s) of orthostatic hypotension (reduction of SBP of \>20 mm Hg or DBP of \>10 mm Hg within 3 minutes of standing) in the past year
* History of myocardial infarction, unstable angina, syncope, or cerebrovascular accident in prior 6 months
* Evidence of alcoholism or drug abuse
* Severe comorbid conditions (i.e., neoplasms or HIV positive or AIDS)
* Current pregnancy or anticipated pregnancy during the study.

Contacts and Locations

Study Contact

Dana Leach, DNP

CONTACT

352-273-8933

leachdd@medicine.ufl.edu

Sarah Long, RN

CONTACT

352-273-8933

sarah.long@medicine.ufl.edu

Principal Investigator

Steven M Smith, PharmD, MPH

PRINCIPAL_INVESTIGATOR

University of Florida

Study Locations (Sites)

UF Health Cardiology - Heart & Vascular Hospital

Gainesville, Florida, 32610

United States

Collaborators and Investigators

Sponsor: University of Florida

Steven M Smith, PharmD, MPH, PRINCIPAL_INVESTIGATOR, University of Florida

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-01-08

Study Completion Date2028-07

Study Record Updates

Study Start Date2025-01-08

Study Completion Date2028-07

Terms related to this study

Keywords Provided by Researchers

minocycline
blood pressure

Additional Relevant MeSH Terms

Hypertension, Resistant to Conventional Therapy